# Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Study · id `cardio:ct-nct02273726` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02273726](<https://clinicaltrials.gov/study/NCT02273726>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02273726

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 741 participants.

## Technical summary

Registry record NCT02273726. Randomized; no masking; primary purpose treatment. Start 2015-01-15 (actual); primary completion 2018-09-19 (actual). Results posted on 2021-10-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 741 participants (enrolled count; ClinicalTrials.gov record NCT02273726, source copy `cardio:ctgov-nct02273726-2021-10-29`, retrieved 2026-10-26)
- Started: 2015-01-15 (actual) (ClinicalTrials.gov record NCT02273726, source copy `cardio:ctgov-nct02273726-2021-10-29`, retrieved 2026-10-26)
- Primary completion: 2018-09-19 (actual) (ClinicalTrials.gov record NCT02273726, source copy `cardio:ctgov-nct02273726-2021-10-29`, retrieved 2026-10-26)
- Completion: 2018-09-19 (actual) (ClinicalTrials.gov record NCT02273726, source copy `cardio:ctgov-nct02273726-2021-10-29`, retrieved 2026-10-26)
- Results first posted: 2021-10-29 (ClinicalTrials.gov record NCT02273726, source copy `cardio:ctgov-nct02273726-2021-10-29`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02273726, source copy `cardio:ctgov-nct02273726-2021-10-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02273726-2021-10-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
- Condition: CKD Anemia in Stable Dialysis Patients
- Intervention (Drug): Epoetin Alfa
- Intervention (Drug): Roxadustat
- Lead sponsor: Kyntra Bio
- Lead sponsor class: INDUSTRY
- Collaborator: Astellas Pharma Europe B.V.
- Collaborator class: INDUSTRY
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Kyntra Bio (`cardio:org-kyntra-bio`)
- Registry lists this organization as a collaborator: Astellas Pharma Europe B.V. (`cardio:org-astellas-pharma-europe-b-v`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: ea161e1b2c7f26a6a4f30a312911cc420cdcfe4e04ea3f29b35d85d434004d34
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
